Genmab A (GMAB) EBIAT: 2018-2021
- Genmab A's EBIAT rose 368.57% to $130.14 in Q2 2021 from the same period last year, while for Jun 2021 it was $275.33, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $552.7 million for FY2020, which is 145.38% up from last year.
- As of Q2 2021, Genmab A's EBIAT stood at $130.14, which was up 111.38% from $61.57 recorded in Q4 2020.
- In the past 5 years, Genmab A's EBIAT registered a high of $19.8 million during Q4 2018, and its lowest value of -$9.0 million during Q2 2019.
- For the 3-year period, Genmab A's EBIAT averaged around -$1.8 million, with its median value being $55.85 (2019).
- Its EBIAT has fluctuated over the past 5 years, first slumped by 100.00% in 2019, then spiked by 368.57% in 2021.
- Genmab A's EBIAT (Quarterly) stood at $19.8 million in 2018, then slumped by 100.00% to $55.85 in 2019, then increased by 10.25% to $61.57 in 2020, then skyrocketed by 368.57% to $130.14 in 2021.
- Its last three reported values are $130.14 in Q2 2021, $61.57 for Q4 2020, and $27.77 during Q2 2020.
